You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
麗珠醫藥(01513.HK)董事會已批准重組以優化集團不同子公司戰略定位
格隆匯 12-04 22:56

格隆匯12月4日丨麗珠醫藥(01513.HK)發佈公告,於2020年12月4日,董事會已批准重組,並且公司已與其他各訂約方訂立有關麗珠生物及目標公司(麗珠單抗、卡迪及麗珠香港)的重組框架協議,據此,各訂約方有條件同意訂立一系列交易以簡化及優化重組集團的資本及股權結構。

重組完成後,目標公司將成為麗珠生物的全資子公司,而麗珠生物將由公司擁有約51%。因此,麗珠生物及目標公司將繼續作為公司的子公司,其資產、負債及業績將繼續合併至公司的合併財務報表。

據悉,麗珠單抗為於中國註冊成立的有限公司,主要從事生物醫藥產品的研究、開發及商品化。卡迪為於中國註冊成立的有限公司,主要從事細胞療法的研究、開發及商品化。麗珠香港為於香港成立的公司,作為投資控股公司運營。截至本公告日期,麗珠香港為麗珠開曼的全資子公司。

公司表示,公司專注醫藥產品的研發、生產及銷售,而麗珠生物及目標公司則為尚未獲取收入的處於臨牀階段生物技術公司,專注治療用生物藥的研發,包括單克隆抗體、重組激素及CAR-T藥物。麗珠開曼(麗珠生物及目標公司於重組前的控股實體)截至2020年9月30日的總資產及截至2019年12月31日止年度的收益及利潤(税前)分別為人民幣15.17億元、零及人民幣649萬元,分別佔公司總資產、收益及利潤的7.85%、零及0.38%。交易乃就重組集團的重組而作出。於重組前後,麗珠生物及目標公司將繼續作為公司的子公司,其資產、負債及業績將繼續合併至公司的合併財務報表。

重組根據所涉子公司各自的主要業務及主要產品將提供更為簡化的資本架構,這將優化集團內不同子公司的戰略定位並提高彼等的業務進展效率。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account